Clinical Trials Browser

Phase 1/2 × Ovarian Neoplasms × tocilizumab × Clear all

NCT03564340 2025-12-03

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Phase 1/2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT01637532 2016-01-26

PITCH

Phase 1/2 Completed

Ovarian Neoplasms